Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Declines By 7.4%

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,010,000 shares, a decrease of 7.4% from the January 15th total of 3,250,000 shares. Based on an average daily volume of 262,600 shares, the short-interest ratio is currently 11.5 days.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KRYS. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday. Finally, Chardan Capital raised their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and an average price target of $210.00.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded up $6.45 during midday trading on Thursday, hitting $182.62. The company's stock had a trading volume of 555,760 shares, compared to its average volume of 259,856. The stock has a market capitalization of $5.25 billion, a price-to-earnings ratio of 103.18 and a beta of 0.84. The stock's 50 day simple moving average is $157.18 and its 200 day simple moving average is $175.18. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the business earned $0.30 earnings per share. The firm's revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, analysts anticipate that Krystal Biotech will post 3.22 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 14.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE boosted its holdings in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in Krystal Biotech by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after purchasing an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after acquiring an additional 121 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after acquiring an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC raised its stake in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after acquiring an additional 123 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).